OIPE	Attorney's Docket No. <u>029395-017</u>
AUG 0 2 2002 IN THE UNITED STATES PATE	NT AND TRADEMARK OFFICE RECEIVED
In restatent Application of) AUG 0 7 2002
Joyce TAYLOR-PAPADIMITRIOU et al.	Group Art Unit: 1644 TECH CENTER 1600/2900
Application No.: 09/658,621	Examiner: Amy M. Decloux
Filed: September 8, 2000) Confirmation No.: 3359
For: MUC-1 DERIVED PEPTIDES	3/8/02

RESPONSE

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Notice to Comply mailed July 2, 2002 (Paper No. 12), please amend the above-identified application as follows.

IN THE SPECIFICATION:

Please replace the paragraph bridging pages 30-31, as follows:

Figure 11 shows that MUC1 derived HLA-A*0201 binding peptides induce peptide specific cytotoxic CTL responses. A2Kb mice were immunised twice with 100µg of MUC1 peptide in IFA and 140µg of Th peptide on day -28 and -14. On day 0 single cell splenocyte suspensions were restimulated in vitro for one week with peptide loaded syngeneic LPSelicited lymphoblasts and tested for cytotoxicity of peptide loaded Jurkat-A*0201Kb. Groups of A2Kb mice were immunised with MUC1 peptides MUC1264-272 (FLSFHISNL; SEQ ID NO:4), MUC1⁴⁶⁰⁻⁴⁶⁸ (SLSYTNPAV; SEQ ID NO:6), MUC1¹³⁻²¹ (LLLTVLTVV; SEQ ID